Patients with Neovascular Age-Related Macular Degeneration Requiring Intensive Intravitreal Aflibercept Treatment: An ARIES Post Hoc Analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2193-6528
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Patients with Neovascular Age-Related Macular Degeneration Requiring Intensive Intravitreal Aflibercept Treatment: An ARIES Post Hoc Analysis ; volume:11 ; number:5 ; day:12 ; month:7 ; year:2022 ; pages:1793-1803 ; date:10.2022
Ophthalmology and therapy ; 11, Heft 5 (12.7.2022), 1793-1803, 10.2022
- Creator
-
Wolf, Sebastian
Holz, Frank G.
Midena, Edoardo
Souied, Eric H.
Lambrou, George
Machewitz, Tobias
Allmeier, Helmut
Mitchell, Paul
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40123-022-00541-8
- URN
-
urn:nbn:de:101:1-2022111909273528885038
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wolf, Sebastian
- Holz, Frank G.
- Midena, Edoardo
- Souied, Eric H.
- Lambrou, George
- Machewitz, Tobias
- Allmeier, Helmut
- Mitchell, Paul
- SpringerLink (Online service)
Other Objects (12)
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration
Choroidal Thickness Changes After Intravitreal Aflibercept Injections in Treatment-Naïve Neovascular AMD
Visual and anatomical outcomes associated with treat-and-extend administration of intravitreal aflibercept for neovascular age-related macular degeneration
The effect of four loading intravitreal aflibercept injections on macular fluid in treatment-naïve neovascular age-related macular degeneration
Clinical characteristics and intravitreal aflibercept outcomes in patients aged 90 years and older with neovascular age-related macular degeneration
Intravitreal Aflibercept in Japanese Patients with Neovascular Glaucoma: The VEGA Randomized Clinical Trial
Intravitreal Aflibercept Treatment Strategies in Routine Clinical Practice of Neovascular Age-Related Macular Degeneration in Belgium: A Retrospective Observational Study
Long term results of patients with neovascular age-related macular degeneration switched from other anti-VEGF agents to intravitreal Aflibercept
Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration
Choroidal Thickness Changes After Intravitreal Aflibercept Injections in Treatment-Naïve Neovascular AMD
Visual and anatomical outcomes associated with treat-and-extend administration of intravitreal aflibercept for neovascular age-related macular degeneration
The effect of four loading intravitreal aflibercept injections on macular fluid in treatment-naïve neovascular age-related macular degeneration
Clinical characteristics and intravitreal aflibercept outcomes in patients aged 90 years and older with neovascular age-related macular degeneration
Intravitreal Aflibercept in Japanese Patients with Neovascular Glaucoma: The VEGA Randomized Clinical Trial
Intravitreal Aflibercept Treatment Strategies in Routine Clinical Practice of Neovascular Age-Related Macular Degeneration in Belgium: A Retrospective Observational Study
Long term results of patients with neovascular age-related macular degeneration switched from other anti-VEGF agents to intravitreal Aflibercept
Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration
Choroidal Thickness Changes After Intravitreal Aflibercept Injections in Treatment-Naïve Neovascular AMD
Visual and anatomical outcomes associated with treat-and-extend administration of intravitreal aflibercept for neovascular age-related macular degeneration
The effect of four loading intravitreal aflibercept injections on macular fluid in treatment-naïve neovascular age-related macular degeneration
Clinical characteristics and intravitreal aflibercept outcomes in patients aged 90 years and older with neovascular age-related macular degeneration
Intravitreal Aflibercept in Japanese Patients with Neovascular Glaucoma: The VEGA Randomized Clinical Trial
Intravitreal Aflibercept Treatment Strategies in Routine Clinical Practice of Neovascular Age-Related Macular Degeneration in Belgium: A Retrospective Observational Study
Long term results of patients with neovascular age-related macular degeneration switched from other anti-VEGF agents to intravitreal Aflibercept